NASDAQ:EQ Equillium Q2 2024 Earnings Report $0.56 -0.15 (-20.66%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$0.58 +0.01 (+2.61%) As of 07:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Equillium EPS ResultsActual EPS$0.01Consensus EPS -$0.15Beat/MissBeat by +$0.16One Year Ago EPSN/AEquillium Revenue ResultsActual Revenue$13.85 millionExpected Revenue$8.15 millionBeat/MissBeat by +$5.70 millionYoY Revenue GrowthN/AEquillium Announcement DetailsQuarterQ2 2024Date8/8/2024TimeN/AConference Call DateThursday, August 8, 2024Conference Call Time4:00PM ETUpcoming EarningsEquillium's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Equillium Earnings HeadlinesEquillium Shares Drop 12.4% After Unveiling Cryptocurrency Treasury StrategyAugust 4 at 2:40 PM | msn.comSpotlight On 3 Promising Penny Stocks With Over $20M Market CapAugust 4 at 9:38 AM | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 5 at 2:00 AM | Crypto 101 Media (Ad)Equillium stock falls after announcing cryptocurrency treasury strategyAugust 4 at 9:38 AM | au.investing.comEquillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve StrategyAugust 4 at 8:30 AM | businesswire.comInterleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightJuly 11, 2025 | finance.yahoo.comSee More Equillium Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email. Email Address About EquilliumEquillium (NASDAQ:EQ), a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.View Equillium ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead? Upcoming Earnings Fortinet (8/6/2025)Airbnb (8/6/2025)DoorDash (8/6/2025)AppLovin (8/6/2025)Energy Transfer (8/6/2025)Sony (8/6/2025)Manulife Financial (8/6/2025)Novo Nordisk A/S (8/6/2025)Realty Income (8/6/2025)Brookfield Asset Management (8/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.